TVTX PE Ratio & Valuation,Is TVTX Overvalued

TVTX Relative Valuation

TVTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TVTX is overvalued; if below, it's undervalued.

Historical Valuation

Travere Therapeutics Inc (TVTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 37.83. The fair price of Travere Therapeutics Inc (TVTX) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 33.89 USD , Travere Therapeutics Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：33.89

Fair

Undervalued

35.09

16.66

EV/EBITDA

Travere Therapeutics Inc. (TVTX) has a current EV/EBITDA of 16.66. The 5-year average EV/EBITDA is 12.04. The thresholds are as follows: Strongly Undervalued below -136.80, Undervalued between -136.80 and -62.38, Fairly Valued between 86.46 and -62.38, Overvalued between 86.46 and 160.88, and Strongly Overvalued above 160.88. The current Forward EV/EBITDA of 16.66 falls within the Historic Trend Line -Fairly Valued range.

-152.62

EV/EBIT

Travere Therapeutics Inc. (TVTX) has a current EV/EBIT of -152.62. The 5-year average EV/EBIT is -13.92. The thresholds are as follows: Strongly Undervalued below -71.44, Undervalued between -71.44 and -42.68, Fairly Valued between 14.84 and -42.68, Overvalued between 14.84 and 43.60, and Strongly Overvalued above 43.60. The current Forward EV/EBIT of -152.62 falls within the Strongly Undervalued range.

5.36

Travere Therapeutics Inc. (TVTX) has a current PS of 5.36. The 5-year average PS is 5.32. The thresholds are as follows: Strongly Undervalued below 1.38, Undervalued between 1.38 and 3.35, Fairly Valued between 7.29 and 3.35, Overvalued between 7.29 and 9.27, and Strongly Overvalued above 9.27. The current Forward PS of 5.36 falls within the Historic Trend Line -Fairly Valued range.

56.77

P/OCF

Travere Therapeutics Inc. (TVTX) has a current P/OCF of 56.77. The 5-year average P/OCF is -8.09. The thresholds are as follows: Strongly Undervalued below -38.44, Undervalued between -38.44 and -23.26, Fairly Valued between 7.08 and -23.26, Overvalued between 7.08 and 22.25, and Strongly Overvalued above 22.25. The current Forward P/OCF of 56.77 falls within the Strongly Overvalued range.

97.57

P/FCF

Travere Therapeutics Inc. (TVTX) has a current P/FCF of 97.57. The 5-year average P/FCF is -0.04. The thresholds are as follows: Strongly Undervalued below -52.44, Undervalued between -52.44 and -26.24, Fairly Valued between 26.16 and -26.24, Overvalued between 26.16 and 52.36, and Strongly Overvalued above 52.36. The current Forward P/FCF of 97.57 falls within the Strongly Overvalued range.

Travere Therapeutics Inc (TVTX) has a current Price-to-Book (P/B) ratio of 42.82. Compared to its 3-year average P/B ratio of 16.99 , the current P/B ratio is approximately 151.99% higher. Relative to its 5-year average P/B ratio of 12.87, the current P/B ratio is about 232.74% higher. Travere Therapeutics Inc (TVTX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -25.58%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -16.74% , the current FCF yield is about -100.00% lower.

42.82

P/B

Median3y

16.99

Median5y

12.87

-1.84

FCF Yield

Median3y

-25.58

Median5y

-16.74

Competitors Valuation Multiple

The average P/S ratio for TVTX's competitors is 38.97, providing a benchmark for relative valuation. Travere Therapeutics Inc Corp (TVTX) exhibits a P/S ratio of , which is -100% above the industry average. Given its robust revenue growth of 162.11%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of TVTX increased by 94.55% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 62.90M to 164.86M.

The secondary factor is the P/E Change, contributed 50.35%to the performance.

Overall, the performance of TVTX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

162.11%

62.90M → 164.86M

Revenue Growth

-117.91%

-87.05 → 15.59

Margin Expansion

50.35%

-22.20 → -33.38

P/E Change

94.55%

17.42 → 33.89

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Travere Therapeutics Inc (TVTX) currently overvalued or undervalued?

What is Travere Therapeutics Inc (TVTX) fair value?

TVTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Travere Therapeutics Inc (TVTX) is between +Inf to +Inf according to relative valuation methord.

How does TVTX's valuation metrics compare to the industry average?

The average P/S ratio for TVTX's competitors is 38.97, providing a benchmark for relative valuation. Travere Therapeutics Inc Corp (TVTX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 162.11%, this premium appears sustainable.

What is the current P/B ratio for Travere Therapeutics Inc (TVTX) as of Dec 18 2025?

As of Dec 18 2025, Travere Therapeutics Inc (TVTX) has a P/B ratio of 42.82. This indicates that the market values TVTX at 42.82 times its book value.

What is the current FCF Yield for Travere Therapeutics Inc (TVTX) as of Dec 18 2025?

As of Dec 18 2025, Travere Therapeutics Inc (TVTX) has a FCF Yield of 0.00%. This means that for every dollar of Travere Therapeutics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Travere Therapeutics Inc (TVTX) as of Dec 18 2025?

As of Dec 18 2025, Travere Therapeutics Inc (TVTX) has a Forward P/E ratio of 35.09. This means the market is willing to pay $35.09 for every dollar of Travere Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Travere Therapeutics Inc (TVTX) as of Dec 18 2025?

As of Dec 18 2025, Travere Therapeutics Inc (TVTX) has a Forward P/S ratio of 0.00. This means the market is valuing TVTX at $0.00 for every dollar of expected revenue over the next 12 months.

TVTX Valuation

Overview

Forecast

Valuation

Earnings